Calcineurin Inhibitor–Free Mycophenolate Mofetil/Sirolimus Maintenance in Liver Transplantation: The Randomized Spare-the-Nephron Trial
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation. In this prospective, open-label, multicenter study, patients undergoing transplantation from July 2005 to June 2007 who were maintained on MMF/CNI were randomized 4 to 12 weeks after transplantation to receive MMF/SRL (n = 148) or continue MMF/CNI (n = 145) and included in the intent-to-treat population. The primary efficacy endpoints were the mean percentage change in the calculated glomerular filtration rate (GFR) and a composite of biopsy-proven acute rejection (BPAR), graft lost, death, and lost to follow-up 12 months after transplantation. Patients were followed for a median of 519 days after randomization. MMF/SRL was associated with a significantly greater renal function improvement from baseline with a mean percentage change in GFR of 19.7 ± 40.6 (versus 1.2 ± 39.9 for MMF/CNI, P = 0.0012). The composite endpoint demonstrated the noninferiority of MMF/SRL versus MMF/CNI (16.4% versus 15.4%, 90% confidence interval = −7.1% to 9.0%). The incidence of BPAR was significantly greater with MMF/SRL (12.2%) versus MMF/CNI (4.1%, P = 0.02). Graft loss (including death) occurred in 3.4% of the MMF/SRL-treated patients and in 8.3% of the MMF/CNI-treated patients (P = 0.04). Malignancy-related deaths were less frequent with MMF/SRL. Adverse events caused withdrawal for 34.2% of the MMF/SRL-treated patients and for 24.1% of the MMF/CNI-treated patients (P = 0.06). The use of MMF/SRL is an option for liver transplant recipients who can benefit from improved renal function but is associated with an increased risk of rejection (but not graft loss). Liver Transpl 19:675–689, 2013.. © 2013 AASLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
Cited by
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
“Between 2000 and 2010, the Food and Drug Administration approved several generic formulations of CNIs (both CsA and Tac) and antimetabolites (both MMF and AZA).”
ResultInfluentialCharlton, M., Levitsky, J., Aqel, B., O'Grady, J., Hemibach, J., Rinella, M., Fung, J., Ghabril, M., Thomason, R., Burra, P., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002147 · Cited by 310
Self-citationLiver transplantation: Current status and challenges
Jadlowiec, C. C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i18.4438 · Cited by 302
Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update
Staatz, C. E., & Tett, S. E. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1247-1 · Cited by 206
“A prospective, open label study in liver transplantation included 148 recipients maintained on MMF and sirolimus , and no calcineurin inhibitor (Teperman et al. 2013).”
BackgroundNelson, J., Alvey, N., Bowman, L., Schulte, J., Segovia, M. C., McDermott, J., Te, H. S., Kapila, N., Levine, D. J., Gottlieb, R. L., et al. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2716 · Cited by 130
Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients
Levitsky, J., Kandpal, M., Guo, K., Kleiboeker, S., Sinha, R., & Abecassis, M. (2022) · American Journal of Transplantation · doi:10.1111/ajt.16835 · Cited by 102
Levitsky, J., Asrani, S. K., Schiano, T., Moss, A., Chavin, K., Miller, C., Guo, K., Zhao, L., Kandpal, M., Bridges, N., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15953 · Cited by 44
Metadata
- Authors
- Teperman, L., Moonka, D., Sebastian, A., Sher, L., Marotta, P., Marsh, C., Koneru, B., Goss, J., Preston, D., & Roberts, J. P.
- Venue
- Liver Transplantation
- Published
- 2013-07
- Volume
- 19
- Issue
- 7
- Pages
- 675-689
- ISSN
- 1527-6465 (ISSN-L)
- OpenAlex
- W1669000468
- Cited by
- 109
- References
- 1
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.